PaizaBio has gained approval from China’s FDA (CFDA) to add new aseptic injectable production capability at it production facility in Hangzhou, China. This expansion will increase the company’s annual fill/finish capacity from 300 million units to 400 million, including vials, pre-filled syringes and cartridges.   The capacity will focus on small molecule drugs for clinical trials and small batch production and the company anticipates reaching full-scale production by 1Q17.   PaizaBio founde...